AAPL 196.98 1.395% MSFT 367.78 -1.0307% NVDA 101.49 -2.8711% GOOGL 151.16 -1.4152% GOOG 153.36 -1.3762% AMZN 172.61 -0.9866% META 501.48 -0.1652% AVGO 170.99 -2.0732% LLY 839.96 14.2958% TSLA 241.37 -0.0745% TSM 151.74 0.0462% V 329.61 -0.5191% JPM 231.96 1.0235% UNH 454.11 -22.3797% NVO 58.08 -7.6336% WMT 93.22 2.2261% LVMUY 110.1 1.0741% XOM 106.92 2.6202% LVMHF 559.0 1.7288% MA 517.33 0.7596%
Last update at 2025-01-03T14:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?
Sat 01 Mar 25, 07:42 PMBeiGene Stock Meets 80-Plus RS Rating Benchmark
Wed 15 Jan 25, 08:44 PMBeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
Wed 16 Oct 24, 10:00 AMHere’s Why BeiGene, Ltd. (BGNE) Rallied in Q3
Thu 10 Oct 24, 02:09 PMBeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
Mon 07 Oct 24, 09:04 AM3 Stocks That May Be Trading Below Intrinsic Value By Up To 48.2%
Fri 27 Sep 24, 01:06 PMGlobal Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
Thu 26 Sep 24, 10:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -1961.03700M | -1438.58800M | -1618.19400M | -943.58600M | -689.82900M |
| Minority interest | 0.00000M | 0.00000M | -3.61700M | 16.15M | 14.45M |
| Net income | -2003.81500M | -1413.35400M | -1600.52300M | -950.57800M | -673.76900M |
| Selling general administrative | 1277.85M | 990.12M | 600.18M | 388.25M | 195.38M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | -511.06200M | -447.86200M | -1056.66000M | -570.31600M | -509.49000M |
| Reconciled depreciation | 66.28M | 0.75M | 31.79M | 18.62M | 10.39M |
| Ebit | -1789.66500M | -1438.73500M | -1657.68200M | -959.89100M | -689.56500M |
| Ebitda | -1788.91400M | -1437.98500M | -1656.83600M | -958.56500M | -679.17700M |
| Depreciation and amortization | 0.75M | 0.75M | 0.85M | 1.33M | 10.39M |
| Non operating income net other | - | 15.90M | 37.49M | 7.17M | 1.99M |
| Operating income | -1789.66500M | -1438.73500M | -1657.68200M | -959.89100M | -705.76900M |
| Other operating expenses | 3205.59M | 2615.02M | 1966.56M | 1388.10M | 903.99M |
| Interest expense | 52.48M | -15.75700M | 43.10M | 9.13M | 13.95M |
| Tax provision | 42.78M | -25.23400M | -17.67100M | 6.99M | -15.79600M |
| Interest income | - | - | 2.00M | - | - |
| Net interest income | 52.48M | -15.75700M | 2.00M | 9.13M | 13.95M |
| Extraordinary items | - | - | - | 63.40M | -1.53800M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 42.78M | -25.23400M | -17.67100M | 6.99M | -15.79600M |
| Total revenue | 1415.92M | 1176.28M | 308.87M | 428.21M | 198.22M |
| Total operating expenses | 1278.60M | 990.87M | 601.02M | 389.57M | 196.28M |
| Cost of revenue | 1926.98M | 1624.14M | 1365.53M | 998.53M | 707.71M |
| Total other income expense net | -171.37200M | 0.15M | 39.49M | 16.30M | 15.94M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2003.81500M | -1413.35400M | -1600.52300M | -950.57800M | -674.03300M |
| Net income applicable to common shares | -2003.81500M | -1413.35400M | -1596.90600M | -948.62800M | -673.76900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 5805.27M | 6379.29M | 8645.95M | 5600.76M | 1612.29M |
| Intangible assets | 108.86M | 94.57M | 103.35M | 53.73M | 52.81M |
| Earning assets | - | - | - | - | - |
| Other current assets | 205.53M | 190.93M | 246.23M | 132.99M | 85.83M |
| Total liab | 2233.74M | 1995.93M | 2402.96M | 1731.51M | 633.93M |
| Total stockholder equity | 3537.33M | 4383.35M | 6242.99M | 3869.24M | 978.36M |
| Deferred long term liab | - | - | 14.17M | 10.79M | 10.53M |
| Other current liab | 784.39M | 114.34M | 479.96M | 127.81M | 152.74M |
| Common stock | 0.14M | 0.14M | 0.13M | 0.12M | 0.08M |
| Capital stock | 0.14M | 0.14M | 0.13M | 0.12M | 0.08M |
| Retained earnings | -7962.05000M | -7080.34200M | -4966.10300M | -3552.74900M | -1955.84300M |
| Other liab | - | 283.74M | 562.47M | 443.26M | 57.09M |
| Good will | - | 0.11M | 0.11M | 0.11M | 0.11M |
| Other assets | 0.00000M | 819.89M | 8645.95M | 186.80M | 108.72M |
| Cash | 3183.27M | 3869.56M | 4375.68M | 1381.95M | 618.01M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1810.11M | 1018.02M | 1599.56M | 1075.20M | 286.04M |
| Current deferred revenue | 0.30M | 255.89M | 407.70M | 366.52M | - |
| Net debt | -2253.08800M | -2978.43700M | -3681.03400M | -819.98600M | -340.66900M |
| Short term debt | 710.32M | 353.01M | 449.49M | 348.91M | 10.81M |
| Short long term debt | 688.37M | 328.97M | 427.56M | 335.01M | - |
| Short long term debt total | 930.18M | 891.13M | 694.64M | 561.96M | 277.34M |
| Other stockholder equity | 11598.69M | 11540.98M | 11191.01M | 7414.93M | 2942.12M |
| Property plant equipment | - | 955.91M | 587.61M | 357.69M | 324.92M |
| Total current assets | 4203.41M | 4713.46M | 7613.88M | 4960.69M | 1172.70M |
| Long term investments | 89.64M | 91.78M | 100.79M | 49.34M | - |
| Net tangible assets | - | 4342.63M | 6242.99M | 3864.24M | 956.25M |
| Short term investments | 2.60M | 665.25M | 2241.96M | 3268.72M | 364.73M |
| Net receivables | 395.89M | 173.17M | 500.18M | 79.67M | 72.81M |
| Long term debt | 197.62M | 209.15M | 202.11M | 183.64M | 240.69M |
| Inventory | 416.12M | 282.35M | 242.63M | 89.29M | 28.55M |
| Accounts payable | 315.11M | 294.78M | 262.40M | 231.96M | 122.49M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | 16.15M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -99.44600M | -77.41700M | 17.95M | 6.94M | -8.00100M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.13M | 0.12M | 0.08M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -4966.10300M | -3552.74900M | -1955.84300M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -18.71000M | -186.45600M | 30.65M | 24.62M | 2.48M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1601.86M | 845.95M | 1032.07M | 640.07M | 439.59M |
| Capital lease obligations | 44.20M | 58.56M | 64.97M | 43.31M | 36.65M |
| Long term debt total | - | - | 202.11M | 183.64M | 240.69M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 1077.12M | 955.51M | -2939.33300M | 712.77M | -458.47900M |
| Change to liabilities | -156.16800M | 427.71M | 255.45M | 82.30M | 87.62M |
| Total cashflows from investing activities | 1077.12M | 640.66M | -3168.36600M | 554.16M | -637.61300M |
| Net borrowings | -65.93500M | 101.53M | 289.60M | 34.68M | 33.58M |
| Total cash from financing activities | -18.97100M | 3636.91M | 5202.83M | 85.68M | 1690.54M |
| Change to operating activities | 41.14M | 30.30M | 100.97M | 49.49M | -11.33000M |
| Net income | -2003.81500M | -1413.35400M | -1600.52300M | -950.57800M | -674.03300M |
| Change in cash | -507.85000M | 2992.88M | 769.23M | -119.93800M | 501.11M |
| Begin period cash flow | 4382.89M | 1390.01M | 620.77M | 740.71M | 239.60M |
| End period cash flow | 3875.04M | 4382.89M | 1390.01M | 620.77M | 740.71M |
| Total cash from operating activities | -1496.61900M | -1298.72300M | -1283.46100M | -750.26900M | -547.71700M |
| Issuance of capital stock | 0.00000M | 3442.62M | 4232.02M | 0.00000M | 1633.37M |
| Depreciation | 66.28M | 46.46M | 31.79M | 18.62M | 10.39M |
| Other cashflows from investing activities | - | -51.90900M | -111.52500M | -69.00000M | -108.85100M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -56.68900M | -153.33300M | -58.90600M | -12.31100M | -5.31200M |
| Change to account receivables | 304.11M | -423.01900M | 10.36M | -29.82200M | -11.62800M |
| Sale purchase of stock | - | 3535.38M | 4325.12M | 51.00M | 29.25M |
| Other cashflows from financing activities | 398.11M | 516.05M | 1115.12M | 118.49M | 65.90M |
| Change to netincome | 308.53M | 186.52M | 248.68M | 184.48M | 133.36M |
| Capital expenditures | 469.10M | 314.85M | 229.03M | 158.61M | 140.84M |
| Change receivables | - | -423.01900M | 10.36M | -29.82200M | -3.93300M |
| Cash flows other operating | - | 188.09M | -170.30500M | -42.95600M | -87.76900M |
| Exchange rate changes | - | - | - | -9.51200M | -4.09600M |
| Cash and cash equivalents changes | - | 2978.85M | 751.00M | -119.93800M | 501.11M |
| Change in working capital | 132.39M | -118.34500M | 150.58M | -10.83300M | -17.21400M |
| Stock based compensation | 303.16M | 240.71M | 183.48M | 134.15M | 87.13M |
| Other non cash items | 3.31M | -13.10800M | -20.98500M | 67.60M | 67.96M |
| Free cash flow | -1965.71800M | -1613.57400M | -1512.49400M | -908.88100M | -688.55300M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BGNE BeiGene Ltd |
-3.89 2.11% | 180.82 | - | - | 6.34 | 4.17 | 5.43 | -11.9104 |
| NVO Novo Nordisk A/S |
-4.8 7.63% | 58.08 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.79 4.46% | 59.70 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.21 0.66% | 489.10 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
13.88 2.53% | 563.16 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
94 Solaris Avenue, Grand Cayman, Cayman Islands, KY1-1108
| Name | Title | Year Born |
|---|---|---|
| Mr. John V. Oyler | Co-Founder, Exec. Chairman & CEO | 1968 |
| Dr. Xiaobin Wu Ph.D. | Pres, COO & GM of China | 1962 |
| Dr. Xiaodong Wang Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director | 1963 |
| Ms. Julia Wang | CFO & Principal Accounting Officer | 1971 |
| Mr. Wang Lai | Global Head of R&D | 1977 |
| Mr. Daniel Maller | VP of Fin. & Accounting | NA |
| Ms. Mi Zhou | Sr. Director of Investor Relations | NA |
| Mr. Kevin C. Mannix | Sr. VP of Investor Relations. | NA |
| Ms. Diana Lee Francis | VP and Global Head of Quality & Regulatory Compliance | NA |
| Mr. Chan Lee | Gen. Counsel | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...